Newborn Screening

Newborn Screening, One Punch - Four Results.

One Punch - Four Results

Early screening, diagnosis and proper treatment can decrease newborn morbidity, mortality and improve the infant's quality of life and life expectancy.

Millions of infants have blood drawn from their heel after birth to detect rare disorders that could threaten their life and long-term health. For most of these disorders, there is no medical history of the condition in the family and no way to predict the health of a baby based on the health of the parents.

The NeoPlex4® Assay simultaneously tests four analytes, T4, hTSH, 17-OHP and IRT, which can be indicators of congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH), and cystic fibrosis (CF phenotypic). Each of these conditions can cause severe mental and physical disability if untreated. If detected early through testing, effective treatment can be initiated. Multiplexing these tests together from one blood spot punch offers significant improvements in testing efficiency to newborn screening laboratories around the world. With a growing number of laboratories screening for more disorders, testing efficiently and using only a small amount of sample is increasingly important.

From a single bloodspot punch, your lab can achieve multiple benefits such as workflow improvements, increased throughput, test consolidation and sample preservation. One punch. Multiple results.

*The NeoPlex® System and the NeoPlex4 assay are CE-IVD (For in vitro diagnostic use). Products are region specific and may not be approved in some countries. Please contact Luminex to obtain the appropriate information for your country of residence.

For more information visit our xMAP Neoplex 4 webpage.

improve the infant's quality of life and life expectancy

Registration and more information xSAMPLES

xSAMPLES

Bookmark and Share